| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 26, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Jul 20, 2022
The Company will also be providing an update to its distributors and other customers on July 26 at 11 am CT. SALT LAKE CITY, July 20, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the...
-
Jul 11, 2022
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
-
Jun 28, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Jun 15, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Jun 9, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
May 26, 2022
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
-
May 19, 2022
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
-
May 12, 2022
Strong results highlighted by record first quarter revenue of $22.7 million and diluted EPS of $0.34 SALT LAKE CITY, May 12, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular...
-
May 3, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...